Assessment of a cytoprotection assay for the discovery and evaluation of anti-human immunodeficiency virus compounds utilizing a genetically-impaired virus

被引:47
|
作者
Kiser, R [1 ]
Makovsky, S [1 ]
Terpening, SJ [1 ]
Laing, N [1 ]
Clanton, DJ [1 ]
机构
[1] NCI,FREDERICK CANC RES & DEV CTR,SAIC FREDERICK,AIDS DRUG SCREENING & DEV LAB,FREDERICK,MD 21702
关键词
human immunodeficiency virus; cytoprotection assay; antiviral activity;
D O I
10.1016/0166-0934(95)01998-7
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A biologically contained cytoprotection assay was developed to screen inhibitors of the human immunodeficiency virus without the need for high level containment or practices. The virus used has multiple point mutations that have destroyed its ability to produce both Rev and Tat, proteins essential for virus replication in vitro. The original cell line employed (CEM-SSTART) contains a genetic construct that allows for the continuous expression of both Rev and Tat, and a subclone (1A2) was developed that provides for maximum acute cytopathic effect. The National Cancer Institute's AIDS drug screening assay was used to rest known drugs with both HIVIIIB virus in the T4 lymphocytic cell line CEM-SS and mutant virus in the 1A2 subclone. This cell-based assay uses the tetrazolium salt, XTT, as an indicator of cellular metabolism after the cells have been infected with virus. The results of extensive testing have shown that the assay using mutant virus is comparable to the current NCI AIDS drug screen. After 42 days in 1A2 or CEM-SS cell culture, the virus or the integrated genome did not revert to wild-type, and the virus produced in 1A2 cells was unable to replicate in PBMCs. Mutant viral stocks were devoid of wild-type virus as determined by a PCR assay that would have found 60-600 copies of mutant RNA. These materials, which are now available to the scientific community (NIH AIDS Research and Reference Reagent Program), should be useful tools to screen and test compounds for potential inhibition of HIV in laboratories not equipped to maintain and use wild-type infectious virus.
引用
收藏
页码:99 / 109
页数:11
相关论文
共 50 条
  • [21] NMR study of dideoxynucleotides with anti-human immunodeficiency virus (HIV) activity
    Reddy, DV
    Jagannadh, B
    Kunwar, AC
    JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, 1996, 31 (3-4): : 113 - 121
  • [22] New developments in combination chemotherapy of anti-human immunodeficiency virus drugs
    Johnson, V.A.
    Hirsch, M.S.
    Annals of the New York Academy of Sciences, 1990, 616
  • [23] Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS
    Fletcher, CV
    Goodroad, BK
    Cummins, LM
    Henry, K
    Balfour, HH
    Rhame, FS
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) : 1571 - 1574
  • [24] NEONATAL PREVALENCE OF ANTI-HUMAN IMMUNODEFICIENCY VIRUS-ANTIBODIES IN CALIFORNIA
    TRACHTENBERG, AI
    CAPELL, FJ
    VUGIA, DJ
    ASCHER, MS
    KIZER, KW
    PEDIATRICS, 1989, 84 (04) : 745 - 746
  • [25] Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides
    Du, JF
    Surzhykov, S
    Lin, JS
    Newton, MG
    Cheng, YC
    Schinazi, RF
    Chu, CK
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (19) : 2991 - 2993
  • [26] A MICROTITER CELL-CULTURE ASSAY FOR THE DETERMINATION OF ANTI-HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODY-ACTIVITY
    ROBERTSON, GA
    KOSTEK, BM
    SCHLEIF, WA
    LEWIS, JA
    EMINI, EA
    JOURNAL OF VIROLOGICAL METHODS, 1988, 20 (03) : 195 - 202
  • [27] Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1
    Adelson, ME
    Pacchia, AL
    Kaul, M
    Rando, RF
    Ron, Y
    Peltz, SW
    Dougherty, JP
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) : 501 - 508
  • [28] EVALUATION OF A RAPID PEPTIDE-BASED ANTI-HUMAN IMMUNODEFICIENCY VIRUS-1 ANTIBODY IMMUNOASSAY
    GREEN, TD
    SEDMAK, DD
    GROSE, MP
    FEATHERINGHAM, NC
    NEFF, JC
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 97 (06) : 854 - 857
  • [29] Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides.
    Du, JF
    Surzhykov, S
    Lin, JS
    Newton, MG
    Cheng, YC
    Schinazi, RF
    Chu, CK
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 83 - CARB
  • [30] Synthesis and anti-human immunodeficiency virus activity of 4′-branched (±)-4′-thiostavudines
    Kumamoto, Hiroki
    Nakai, Takahito
    Haraguchi, Kazuhiro
    Nakamura, Kazuo T.
    Tanaka, Hiromichi
    Baba, Masanori
    Cheng, Yung-Chi
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (26) : 7861 - 7867